PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 18640378-3 2008 Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies. Simvastatin 48-59 low density lipoprotein receptor Homo sapiens 82-86 22761797-8 2012 Treatment with cholesterol-lowering simvastatin induced up to 90% reduction in relative cell number of normal cell lines but a 15-20% reduction in relative number of cancer cells, an effect accompanied by sharp upregulation of HMGCR and LDLR. Simvastatin 36-47 low density lipoprotein receptor Homo sapiens 237-241 20413733-0 2010 Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin. Simvastatin 86-97 low density lipoprotein receptor Homo sapiens 22-26 20413733-3 2010 METHODS AND RESULTS: Haplotypes in the LDLR 3"-untranslated region (3-UTR) were tested for association with lipid-lowering response to simvastatin treatment in the Cholesterol and Pharmacogenetics trial (335 blacks and 609 whites). Simvastatin 135-146 low density lipoprotein receptor Homo sapiens 39-43 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 low density lipoprotein receptor Homo sapiens 0-4 20413733-4 2010 LDLR haplotype 5 (LDLR L5) was associated with smaller simvastatin-induced reductions in low-density lipoprotein cholesterol, total cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B (P=0.0002 to 0.03) in blacks but not whites. Simvastatin 55-66 low density lipoprotein receptor Homo sapiens 18-22 20413733-6 2010 We observed similar differences when measuring simvastatin-mediated induction of low-density lipoprotein receptor surface expression using lymphoblast cell lines (P=0.03). Simvastatin 47-58 low density lipoprotein receptor Homo sapiens 81-113 20413733-7 2010 CONCLUSIONS: We have identified a common LDLR 3-UTR haplotype that is associated with attenuated lipid-lowering response to simvastatin treatment. Simvastatin 124-135 low density lipoprotein receptor Homo sapiens 41-45 20946921-5 2011 Its efficacy was further increased by simvastatin, which up-regulates the LDLR levels and contemporarily reduces the Pgp activity, thus increasing the liposomes uptake and limiting the drug efflux. Simvastatin 38-49 low density lipoprotein receptor Homo sapiens 74-78 18640378-3 2008 Our results showed that combination of BBR with simvastatin (SIMVA) increased the LDLR gene expression to a level significantly higher than that in monotherapies. Simvastatin 61-66 low density lipoprotein receptor Homo sapiens 82-86 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 97-101 18547436-9 2008 Immunoblot analyses of endogenous PCSK9 and LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more upregulated than PCSK9 by simvastatin (2.6x vs 1.5x, respectively at 10 muM), while fenofibrate did not induce changes in either. Simvastatin 162-173 low density lipoprotein receptor Homo sapiens 123-127 17980884-8 2008 Simvastatin and the combination of ezetimibe and simvastatin increased the HMG-CoA reductase and LDLR gene expression while ezetimibe had no effect. Simvastatin 49-60 low density lipoprotein receptor Homo sapiens 97-101 17980884-10 2008 The combination of ezetimibe and simvastatin increased the expression of the serine protease proprotein convertase subtilisin/kexin 9 (PCSK9), an enzyme shown to down-regulate LDLR protein levels. Simvastatin 33-44 low density lipoprotein receptor Homo sapiens 176-180 17980884-11 2008 CONCLUSIONS: The co-administration of ezetimibe and simvastatin abrogates the ezetimibe-induced increase in cholesterol synthesis and up-regulates the LDLR gene but not protein expression, an effect possibly mediated through a parallel upregulation of PCSK9 expression. Simvastatin 52-63 low density lipoprotein receptor Homo sapiens 151-155 17079794-3 2007 In these studies, we demonstrate that treatment of J774 macrophages transfected to constitutively express a human apoE3 cDNA with simvastatin, to increase LDL receptor activity, reduces the secretion of apoE. Simvastatin 130-141 low density lipoprotein receptor Homo sapiens 155-167 12208479-10 2002 These results demonstrate that inhibition of cholesterol biosynthesis by lovastatin and simvastatin modifies the normal diurnal rhythm of cholesterol biosynthesis in female FH patients. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 173-175 16545796-5 2006 Furthermore, both EP2300 compounds and simvastatin significantly reduced triglyceride synthesis and apoB secretion and increased LDL receptor expression and LDL uptake in HepG2 cells. Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 129-141 14969613-0 2004 Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 25-54 14969613-0 2004 Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 134-166 14969613-1 2004 The effect of simvastatin therapy on the biologic characteristics of the electronegative low-density lipoprotein (LDL) subfraction of patients with familial hypercholesterolemia (FH) was studied. Simvastatin 14-25 low density lipoprotein receptor Homo sapiens 148-177 14969613-1 2004 The effect of simvastatin therapy on the biologic characteristics of the electronegative low-density lipoprotein (LDL) subfraction of patients with familial hypercholesterolemia (FH) was studied. Simvastatin 14-25 low density lipoprotein receptor Homo sapiens 179-181 14969613-4 2004 The LDL(-) proportion was twofold higher in patients with FH than in NL subjects (17.6 +/- 1.6% vs 7.8 +/- 1.5%, respectively; p <0.05) and was progressively reduced by simvastatin therapy (15.7 +/- 1.6% at 3 months; 13.8 +/- 2.5% at 6 months; p <0.05). Simvastatin 172-183 low density lipoprotein receptor Homo sapiens 58-60 14969613-6 2004 Simvastatin progressively induced changes in lipid content of both LDL subfractions in patients with FH, and lipid composition was closer to these subfractions in NL subjects after 6 months of therapy. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 101-103 14969613-9 2004 Simvastatin-induced changes in LDL composition were accompanied by a progressive increase in affinity of LDL(+) and LDL(-) in patients with FH. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 140-142 14969613-13 2004 We conclude that simvastatin therapy was able to modify LDL subfraction composition in subjects with FH and increase their affinity to the LDL receptor. Simvastatin 17-28 low density lipoprotein receptor Homo sapiens 101-103 14969613-13 2004 We conclude that simvastatin therapy was able to modify LDL subfraction composition in subjects with FH and increase their affinity to the LDL receptor. Simvastatin 17-28 low density lipoprotein receptor Homo sapiens 139-151 12505222-1 2002 OBJECTIVES: This study was designed to determine whether simvastatin improves endothelial function in children with familial hypercholesterolemia (FH). Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 116-145 12505222-1 2002 OBJECTIVES: This study was designed to determine whether simvastatin improves endothelial function in children with familial hypercholesterolemia (FH). Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 147-149 12505222-5 2002 Children with FH were randomized to receive simvastatin or placebo for 28 weeks. Simvastatin 44-55 low density lipoprotein receptor Homo sapiens 14-16 12505222-8 2002 In the simvastatin FH group, FMD improved significantly, whereas the FMD remained unaltered in the placebo FH group throughout the study period (absolute increase 3.9% +/- 4.3% vs. 1.2% +/- 3.9%, p < 0.05). Simvastatin 7-18 low density lipoprotein receptor Homo sapiens 19-21 12505222-9 2002 In the simvastatin FH group, FMD increased to a level similar to the non-FH controls (15.6% +/- 6.8% vs. 15.5% +/- 5.4%, p = 0.958). Simvastatin 7-18 low density lipoprotein receptor Homo sapiens 19-21 12505222-10 2002 Upon treatment, the simvastatin FH group showed significant absolute reductions of total cholesterol (TC) (-2.16 +/- 1.04 mmol/l, 30.1%) and low-density lipoprotein cholesterol (LDL-C) (-2.13 +/- 0.99 mmol/l, 39.8%). Simvastatin 20-31 low density lipoprotein receptor Homo sapiens 32-34 12505222-12 2002 CONCLUSIONS: Our data show significant improvement of endothelial dysfunction towards normal levels after short-term simvastatin therapy in children with FH. Simvastatin 117-128 low density lipoprotein receptor Homo sapiens 154-156 12204807-0 2002 Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. Simvastatin 65-76 low density lipoprotein receptor Homo sapiens 94-123 12204807-9 2002 In conclusion, FH patients with the worst lipoprotein profile showed the greatest benefit from high-dose simvastatin treatment, since changes in these parameters were partly determined by baseline lipid levels. Simvastatin 105-116 low density lipoprotein receptor Homo sapiens 15-17 11181283-0 2001 [Influence of FH Valencia 1 and 2 mutations of the LDL receptor gene on the response to simvastatin in subjects with molecularly defined heterozygous familial hypercholesterolemia in Spain]. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 51-63 11600564-0 2001 Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. Simvastatin 184-195 low density lipoprotein receptor Homo sapiens 105-143 11600564-1 2001 The aims of this study were to examine the presence of mutations in the low-density lipoprotein receptor gene among subjects clinically diagnosed with familial hypercholesterolemia and to analyze whether the molecular diagnosis helps to predict the response to simvastatin treatment in our familial hypercholesterolemia population. Simvastatin 261-272 low density lipoprotein receptor Homo sapiens 72-104 11849659-0 2002 Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Simvastatin 90-101 low density lipoprotein receptor Homo sapiens 13-25 11849659-8 2002 The results of the present study have shown that the contribution of apo E polymorphism and the dosage of simvastatin to the LDL-cholesterol responsiveness is influenced by the nature of the LDL receptor gene mutation. Simvastatin 106-117 low density lipoprotein receptor Homo sapiens 191-203 11181283-9 2001 The type of LDL receptor gene mutation could predict the response to simvastatin in our south European FH population. Simvastatin 69-80 low density lipoprotein receptor Homo sapiens 12-24 11480454-2 2000 Lipophilic inhibitors including mevastatin, simvastatin, atorvastatin and NK-104 were able to increase the levels of mRNAs for HMG-CoA reductase and the LDL receptor, but the hydrophilic inhibitor pravastatin was not effective in Hep G2 cells as had previously been reported. Simvastatin 44-55 low density lipoprotein receptor Homo sapiens 153-165 10669649-16 2000 In FH-NK adults on simvastatin therapy, serum LDL cholesterol levels could be reduced even further by including a stanol ester margarine in the regimen. Simvastatin 19-30 low density lipoprotein receptor Homo sapiens 3-8 10498134-0 1999 Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia. Simvastatin 10-21 low density lipoprotein receptor Homo sapiens 117-146 10498134-4 1999 We evaluated the effect of 6 months of simvastatin therapy (40 mg/day) on electronegative LDL proportion and LDL susceptibility to in vitro induced oxidation in 21 patients with heterozygous familial hypercholesterolemia (FH). Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 191-220 10498134-4 1999 We evaluated the effect of 6 months of simvastatin therapy (40 mg/day) on electronegative LDL proportion and LDL susceptibility to in vitro induced oxidation in 21 patients with heterozygous familial hypercholesterolemia (FH). Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 222-224 10208479-0 1999 The type of mutation in the low density lipoprotein receptor gene influences the cholesterol-lowering response of the HMG-CoA reductase inhibitor simvastatin in patients with heterozygous familial hypercholesterolaemia. Simvastatin 146-157 low density lipoprotein receptor Homo sapiens 28-60 10493153-8 1999 Simvastatin, which stimulates LDLr in man and not in rat, lowers the level of LDL in man and has no effect on the cholesterolemia of the RICO rat. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 30-34 9633944-7 1998 These results show that simvastatin was an effective and well-tolerated therapy for FH in the pediatric population for all LDL receptor gene mutations. Simvastatin 24-35 low density lipoprotein receptor Homo sapiens 84-86 9633944-0 1998 Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Simvastatin 101-112 low density lipoprotein receptor Homo sapiens 24-36 9633944-0 1998 Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Simvastatin 101-112 low density lipoprotein receptor Homo sapiens 157-186 9633944-2 1998 A randomized, double-blind, placebo-controlled clinical trial with simvastatin, an HMG-CoA reductase inhibitor, was conducted in 63 children and adolescents with heterozygous FH. Simvastatin 67-78 low density lipoprotein receptor Homo sapiens 175-177 9633944-6 1998 Multiple regression analyses suggested that 42% of the variation of the LDL cholesterol response to simvastatin can be attributed to variation in the mutant LDL receptor locus, apolipoprotein E genotype, and body mass index, while 35% of the variation in HDL cholesterol response was explained by sex and baseline HDL cholesterol. Simvastatin 100-111 low density lipoprotein receptor Homo sapiens 157-169 9920155-14 1999 This study suggests that a decrease in residence time by upregulation of the LDL receptor with simvastatin alters LDL composition in a way that is likely to render the particle less atherogenic. Simvastatin 95-106 low density lipoprotein receptor Homo sapiens 77-89 9633944-7 1998 These results show that simvastatin was an effective and well-tolerated therapy for FH in the pediatric population for all LDL receptor gene mutations. Simvastatin 24-35 low density lipoprotein receptor Homo sapiens 123-135 9633944-8 1998 Moreover, the nature of LDL receptor gene mutations and other genetic and constitutional factors play a significant role in predicting the efficacy of simvastatin in the treatment of FH in children and adolescents. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 24-36 9633944-8 1998 Moreover, the nature of LDL receptor gene mutations and other genetic and constitutional factors play a significant role in predicting the efficacy of simvastatin in the treatment of FH in children and adolescents. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 183-185 8831932-0 1996 Familial defective apolipoprotein B-100 (FDB): effect of simvastatin therapy on LDL-receptor binding. Simvastatin 57-68 low density lipoprotein receptor Homo sapiens 80-92 8980885-7 1996 Simvastatin promotes more effective reduction in cholesterol and apoB in LDL than in VLDL, probably by increasing the hepatic LDL receptor which preferentially binds LDL. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 126-138 8831932-2 1996 If HMGCoA reductase inhibitors such as simvastatin lowered LDL mainly by up-regulating LDL-receptor mediated clearance, they should decrease the overall binding affinity of LDL from an FDB heterozygote by selectively decreasing LDL bearing normal apo B. Simvastatin 39-50 low density lipoprotein receptor Homo sapiens 87-99 8546515-1 1995 A boy with a total plasma cholesterol concentration of 20.9 mmol/l which fell significantly with a low fat diet, cholestyramine and simvastatin, was shown to have two different mutations in the low density lipoprotein receptor gene, demonstrating that some patients with homozygous familial hypercholesterolaemia show a good lipid lowering response to treatment. Simvastatin 132-143 low density lipoprotein receptor Homo sapiens 194-226 10146335-5 1993 In a subset of these patients who have residual LDL receptor activity, further lowering of the plasma cholesterol concentration was achieved by adding simvastatin, an hydroxy-methylglutaryl coenzyme A reductase inhibitor. Simvastatin 151-162 low density lipoprotein receptor Homo sapiens 48-60 8292093-3 1993 In this paper we show that serum cholesterol in a homozygous FH patient with a receptor-negative LDL-receptor phenotype was reduced by 30% after treatment with simvastatin alone and by a further 11% with simvastatin in combination with probucol and nicotinic acid. Simvastatin 160-171 low density lipoprotein receptor Homo sapiens 97-109 8292093-3 1993 In this paper we show that serum cholesterol in a homozygous FH patient with a receptor-negative LDL-receptor phenotype was reduced by 30% after treatment with simvastatin alone and by a further 11% with simvastatin in combination with probucol and nicotinic acid. Simvastatin 204-215 low density lipoprotein receptor Homo sapiens 97-109 8292099-4 1993 Simvastatin increased the LDL receptor activity of cells from the PH subjects by 70% while lowering their plasma cholesterol by 26%, but reducing the fat intake from 38% to 20% of energy and cholesterol from 239 to 96 mg/day had no effect on the receptor despite a 10% reduction in plasma cholesterol. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 26-38 8292099-5 1993 Upregulation of the LDL receptor may therefore have been involved in the lowering of plasma cholesterol by simvastatin but not by the reduction in dietary fat and cholesterol. Simvastatin 107-118 low density lipoprotein receptor Homo sapiens 20-32 31969989-4 2020 Across phenotypes of statin-induced LDL-C change, baseline adjustment identified variants from six loci meeting genome-wide significance (SORT/CELSR2/PSRC1, LPA, SLCO1B1, APOE, APOB, and SMARCA4/LDLR). Simvastatin 21-27 low density lipoprotein receptor Homo sapiens 195-199 8457250-0 1993 Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Simvastatin 82-93 low density lipoprotein receptor Homo sapiens 39-51 1627634-0 1992 Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes. Simvastatin 112-123 low density lipoprotein receptor Homo sapiens 50-62 1627634-8 1992 Both LDL-receptor and its mRNA levels were raised by simvastatin at concentrations inhibiting cholesterol synthesis. Simvastatin 53-64 low density lipoprotein receptor Homo sapiens 5-17 1627634-9 1992 Our data show that, in this human hepatoma cell line, HMG-CoA reductase competitive inhibition by simvastatin triggers a coordinate regulation of the expression of genes coding for reductase and LDL receptor but not for apo-B. Simvastatin 98-109 low density lipoprotein receptor Homo sapiens 195-207 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 0-11 low density lipoprotein receptor Homo sapiens 191-203 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 24-34 low density lipoprotein receptor Homo sapiens 191-203 2083515-2 1990 Simvastatin (epistatin; synvinolin; MK 733), an HMG-CoA reductase inhibitor, acts by decreasing cholesterol synthesis and by increasing low density lipoprotein (LDL) catabolism via increased LDL receptor activity. Simvastatin 36-42 low density lipoprotein receptor Homo sapiens 191-203 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 93-104 low density lipoprotein receptor Homo sapiens 50-79 1880219-0 1991 Lecithin: cholesterol acyltransferase activity in familial hypercholesterolemia treated with simvastatin and simvastatin plus low-dose colestipol. Simvastatin 109-120 low density lipoprotein receptor Homo sapiens 50-79 2390138-0 1990 Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Simvastatin 51-62 low density lipoprotein receptor Homo sapiens 103-132 2390138-6 1990 In the combined FH patient group (males and females) a considerable interindividual variation in response to simvastatin was observed, but was not related to the apoE polymorphism. Simvastatin 109-120 low density lipoprotein receptor Homo sapiens 16-18 2390138-7 1990 However, considering males and females separately, we found that female FH patients with the apoE3E3 phenotype responded better on simvastatin treatment with respect to LDL-cholesterol than male FH patients with the apoE3E3 phenotype. Simvastatin 131-142 low density lipoprotein receptor Homo sapiens 72-74 2112479-7 1990 Our results indicate that the potent hypocholesterolaemic effects of simvastatin are accompanied by increases in high-affinity LDL receptor-mediated degradation of LDL and a compensatory increase in cholesterol biosynthesis in freshly isolated mononuclear leucocytes but that rates of mevalonic acid excretion in the urine decrease. Simvastatin 69-80 low density lipoprotein receptor Homo sapiens 127-139 33823318-9 2021 Mechanistically, increasing intracellular de novo cholesterol biosynthesis was the chief contributor to the malignant behaviors caused by LDLR inhibition, which could be rescued by simvastatin. Simvastatin 181-192 low density lipoprotein receptor Homo sapiens 138-142 32005714-6 2020 We show here that statins induce a similar accumulation of immature LDLR that is resolved with class II correction. Simvastatin 18-25 low density lipoprotein receptor Homo sapiens 68-72 29569973-7 2018 We found that the combination of simvastatin and BRE caused the synergic induction of LDLR expression and LDL-C uptake, whereas simvastatin alone increased the expression of PCSK9 in the HepG2 cells. Simvastatin 33-44 low density lipoprotein receptor Homo sapiens 86-90 31706904-1 2019 BACKGROUND: Maximal doses of potent statins are the basement of treatment of familial hypercholesterolemia (FH). Simvastatin 36-43 low density lipoprotein receptor Homo sapiens 77-106 30867758-11 2019 Furthermore, as a hydroxymethylglutaryl-Coenzyme A reductase inhibitor, treatment using simvastatin increased LDL receptor expression, leading to enhancement of the TS-PDT effect on MKN74 cells. Simvastatin 88-99 low density lipoprotein receptor Homo sapiens 110-122 30867758-12 2019 In conclusion, the difference in LDL receptor expression between the two gastric cell lines could influence TS-PDT efficacy; simvastatin may enhance the antitumor effect of TS-PDT through upregulating the LDL receptor even on PDT-resistant gastric cancer cells. Simvastatin 125-136 low density lipoprotein receptor Homo sapiens 205-217 31543373-0 2019 Addition of marine omega-3 fatty acids to statins in familial hypercholesterolemia does not affect in vivo or in vitro endothelial function. Simvastatin 42-49 low density lipoprotein receptor Homo sapiens 53-82 29569973-8 2018 These results clearly demonstrated that the BRE from black raspberry suppressed simvastatin-induced PCSK9 expression and improved LDL-C uptake by hepatocytes through the induction of LDLR expression. Simvastatin 80-91 low density lipoprotein receptor Homo sapiens 183-187 27358845-12 2016 In LNCaP cells, the protein level of LDLr was increased by simvastatin. Simvastatin 59-70 low density lipoprotein receptor Homo sapiens 37-41 28812343-8 2017 Finally, we demonstrated that the Mylip/Idol expression and LDLR activity were synergistically changed by a combination of xanthohumol and simvastatin treatment. Simvastatin 139-150 low density lipoprotein receptor Homo sapiens 60-64 27358845-15 2016 After knocking down LDLr expression by siRNA, intracellular cholesterol levels were decreased, and cell proliferation was inhibited by simvastatin in LNCaP cells. Simvastatin 135-146 low density lipoprotein receptor Homo sapiens 20-24 27358845-16 2016 CONCLUSION: Simvastatin inhibited prostate cancer cell growth by decreasing cellular cholesterol and could be more effective in androgen-independent prostate cancer, where there is loss of regulation of LDLr expression. Simvastatin 12-23 low density lipoprotein receptor Homo sapiens 203-207 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 40-42 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 61-65 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 102-106 22528129-6 2012 RESULTS: We found that two heterozygote FH patients with the LDLR mutation p.W556R causing a class II LDLR defect (transport defective LDLR) respond exceedingly well to the treatment with simvastatin 40 mg/ezetimibe 10 mg. Simvastatin 188-199 low density lipoprotein receptor Homo sapiens 102-106